trending Market Intelligence /marketintelligence/en/news-insights/trending/dF_FunwP-cgAO3BiD7tDTA2 content esgSubNav
In This List

Regeneron, Sanofi's eczema drug deemed cost-effective

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Regeneron, Sanofi's eczema drug deemed cost-effective

Regeneron Pharmaceuticals Inc. and Sanofi's eczema drug Dupixent is a good value for the money, price advisory group the Institute for Clinical and Economic Review said in a final review of two eczema options.

The group's conclusion reiterates its positive draft document, released days before Dupixent was approved by the U.S. Food and Drug Administration.

The new drug — which targets moderate-to-severe eczema in adults — is listed at $37,000 but comes out to about $30,000 after discounts and rebates, Regeneron CEO Leonard Schleifer had previously said. In the report, ICER said that manufacturers informed them that the average net U.S. price would not exceed $31,000.

Meanwhile, Pfizer Inc.'s Eucrisa, which targets mild-to-moderate eczema in both adults and children, was not assessed for cost-effectiveness due to data availability challenges and anticipated clinical uptake, according to ICER spokesperson Jerry Berger. Previously, Reuters reported its wholesale priced would be $580 per tube.

The ICER report concluded that there was inadequate evidence on both Eucrisa's efficacy and its safety relative to other treatments.

There is currently no head-to-head data comparing either drug to others in the field. However, while Eucrisa could be compared to existing topical creams on the market, ICER noted that there are very few current options for severe eczema outside of Dupixent, which is an injection.